NAOV

ENvue Medical, Inc., formerly NanoVibronix, Inc., is a medical technology company advancing both non-invasive and minimally invasive solutions across clinical and home care settings. The Company focuses on two distinct technology platforms: Acoustic-based therapeutic technologies, including PainShield and UroShield, which utilize proprietary low-intensity surface acoustic wave (SAW) technology. These devices are intended for use in home or care settings and are designed to treat pain, reduce bacterial colonization, and disrupt biofilms. UroShield is an ultrasound-based product that is designed to prevent bacterial colonization and biofilm in urinary catheters. The ENvue Navigation Platform, which is a minimally invasive electromagnetic navigation system intended to assist clinicians in placing feeding tubes into the gastrointestinal tract. ENvue provides real-time bedside visualization of tube movement and supports informed decision-making during the placement procedure.

Wall Street analysts forecast NAOV stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for NAOV is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Nanovibronix Inc revenue for the last quarter amounts to 722.00K USD, increased 92.02 % YoY.

Nanovibronix Inc. EPS for the last quarter amounts to -0.91 USD, decreased -97.68 % YoY.

Nanovibronix Inc (NAOV) has 15 emplpoyees as of December 15 2025.

Today NAOV has the market capitalization of 1.98M USD.